Deliver Your News to the World

World Infertility Device Leader (OTC BB: IVOB)


Invo Bioscience Inc.

(Public, OTC BB:IVOB)

World Health Organization statistics imply that infertility and sterility will be the third most serious diseases in the 21st century after cancer and cardiovascular diseases, according to a Life Times report.

InvoBioscience is engaged in providing its InvoCell technology to help infertile couples have a baby. It has one principal product, the manufacturing and distribution of the InvoCell technology.

InvoBioscience has rapidly conquered many countries with a big market potential. Distributor contracts have been signed all over the world; registration process for clearance when it is needed has been started as well. Their strategy to focus on other countries first rather than the classic USA FDA path was very well done. InvoBioscience’s incomes have started to growth on each part of the world.

While InvoBioscience has many distribution agreements coming up or already signed for many countries, this article focuses here only on the biggest markets potential.

Chinese Market

Couples in China, the world’s most populous nation, are having difficulty conceiving. Infertility in the country has risen from 12.5 to 15 percent but that number could climb quickly to about 20, according to a report released recently at a forum in Beijing.

The full special report on the company appears today at

Disclosure: Author is Long


About TheMarketFinancial

MiV Investments Inc. can be found at It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews, premium services and other unique content including expert stock analysis from a variety of accredited staff and authors. The company also offers Investor Relations contracting services.

For more financial and investment news, visit

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. TheMarketFinancial.Com on behalf of MiV Investments Inc. does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.